Core Viewpoint - Hualan Co., Ltd. announced a capital increase of 450 million RMB to its wholly-owned subsidiary, Hainan Lingqing Intelligent Pharmaceutical Technology Co., Ltd., to strengthen its capabilities in AI pharmaceutical research and development [1] Group 1: Company Overview - Hainan Lingqing is a key platform for Hualan's business layout in the AI pharmaceutical sector, focusing on innovative drug R&D solutions and services [1] - The subsidiary aims to promote the application and commercialization of AI technology in drug development and industry [1] Group 2: Financial Details - The capital increase will raise the registered capital of Lingqing from 50 million RMB to 500 million RMB [1] - The investment is intended to enhance the subsidiary's capital strength and support future R&D and business expansion [1] Group 3: Strategic Goals - The company aims to improve its ability to link with high-quality industry resources and establish deep cooperation with global upstream and downstream enterprises, technology teams, and research institutions [1] - This move is part of Hualan's overall strategic development goals [1]
华兰股份：以自有资金人民币4.5亿元对全资子公司灵擎数智进行增资